TANDEM DIABETES CARE INC (TNDM): Results of Operations and Financial Condition
TANDEM DIABETES CARE INC (TNDM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-q2earningsrelease2026.htm EX-99.1 Document Exhibit 99.1 Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2026 Financial Results San Diego,
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 revenue, gross margin, and adjusted EBITDA margin based on reaffirmed ranges, plus the reduced estimate for non-cash charges. Product and regulatory updates (510(k) submission, FDA clearance/CE Mark, sensor compatibility) add incremental catalysts that may affect adoption curves.
Market read
The filing combines a quarterly beat on profitability metrics (gross margin and operating loss improvement) with explicit 2026 guidance ranges and a specific reduction in non-cash charges, which can drive re-rating discussions.
What to watch
The guidance discussion references pay-as-you-go reimbursement transition assumptions and international direct operations initiation; any delays or pricing pressure there could offset the reported margin gains.
Background
This is an SEC 8-K (Item 2.02) with an attached earnings release covering Tandem Diabetes Care’s Q2 2026 results and 2026 guidance.
Ticker impact
Tandem Diabetes Care reported Q2 2026 sales of $254.6M, gross margin of 57%, and reaffirmed 2026 guidance with updated non-cash charges.
Likely near-term positive bias if investors focus on margin expansion and the reaffirmed 2026 outlook; watch for any skepticism around operating losses and reimbursement transition assumptions.
The filing provides concrete quarterly results (sales, gross margin, operating loss, adjusted EBITDA) plus explicit 2026 guidance ranges and a specific reduction in non-cash charges, which are actionable for valuation and positioning.
Market effects
Reinforces demand and adoption momentum in insulin delivery systems, with regulatory and sensor-compatibility milestones that can support category sentiment.
U.S. sales growth and pharmacy-channel reimbursement progress may influence near-term expectations for U.S. diabetes device reimbursement dynamics.
International shipment growth and CE Mark expansions support the narrative of scaling beyond the U.S., potentially affecting global medtech risk appetite.
Counterpoint
Despite improved gross margin, the company still reported GAAP and non-GAAP operating losses, so the market may discount the quality of earnings and focus on cash burn and execution risk.
Key entities
- companyTandem Diabetes Care, Inc.
Nasdaq-listed insulin delivery and diabetes technology company reporting Q2 2026 results and reaffirming 2026 guidance.
- regulatorU.S. Food and Drug Administration (FDA)
Referenced for 510(k) submission and FDA clearance for Control-IQ+ use in pregnancy.
- technology_partnerDexcom G7
Compatibility introduced for both t:slim X2 and Tandem Mobi in the U.S.
- technology_partnerAbbott FreeStyle Libre 3 Plus
t:slim X2 compatibility launched in four European markets.
